

FDA-Certified Workshop of Bright Future Pharmaceutical (Hainan) is Successfully Completed

Bright Future Pharmaceutical (Hainan) Co. Ltd., completed the construction of the US FDA cGMP-certified project.

HONG KONG, CHINA, March 11, 2020 /EINPresswire.com/ -- The construction of the US FDA cGMP-certified project, begun in November 2017 by Bright Future Pharmaceutical (Hainan) Co. Ltd., was completed in late 2019 after two years of meticulous development. The completion ceremony represented an important [milestone](#) for Bright Future (Hainan), marking the company's readiness and a great stride towards an [international](#) development strategy. This lays a solid foundation to support Bright Future in promoting its [product](#) brands.



The completion ceremony of the FDA certified workshop of Bright Future Pharmaceutical (Hainan)

The newly-built workshop of approximately 1,500m² in the existing plant area, is in strict accordance with the US FDA cGMP standards, enhancing the production line of Bright Future Pharmaceutical. Facilities employed in the first phase can meet US FDA cGMP certification, and the production requirements of customer demand. Production capacity is expected to increase significantly to around 700 million tablets per year once the second phase of the facility is in place. In addition to the production of tablets, the workshop has reserved sufficient space for the production of capsules and other products to meet future demand.

“

Customers will benefit from the increased flexibility, delivery capacity and efficiency of the newly-built facilities. Our development towards intelligence, efficiency and internationalisation.”

Mike Ma, Vice President of Manufacturing and Supply at Bright Future

Mike Ma, Vice President of Manufacturing and Supply at Bright Future extended warmest welcomes to the distinguished guests attending the ceremony, and said, “The expanded facility is set to bolster the company’s local competitiveness and will enable it to focus completely on the needs of overseas customers while maintaining the high quality of their products. This factory is part of a far-reaching investment program being carried out by the Bright Future to modernise its global development and

production network. Our customers will benefit from the increased flexibility, delivery capacity and efficiency of the newly-built facilities. We always aim our development towards intelligence, efficiency and internationalisation.”

US FDA is the US Food and Drug Administration, and its cGMP (Current Good Manufacturing

Practice) is the international drug manufacturing management regulations. Its certification is an important cornerstone for entering the international drug market.

Maggie Lau
Bright Future Pharmaceutical Laboratories Limited
+852 2211 2447
[email us here](#)
Visit us on social media:
[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.